Curis Inc Q4 revenue misses estimates
Overview
US biotechnology firm's Q4 revenue fell and missed analyst expectations
Outlook
Curis expects current cash and planned warrant proceeds to fund operations into the second half of 2027
Result Drivers
ROYALTY ASSET SALE - Co recognized $27.2 mln non-cash gain and extinguished liability from sale of Erivedge royalty assets
Company press release: ID:nPn33cwXka
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Miss | $1.14 mln | $3.19 mln (5 Analysts) |
Q4 Net Income | Beat | $19.36 mln | -$7.78 mln (5 Analysts) |
Q4 Basic EPS | Beat | $1.23 | -$0.45 (5 Analysts) |
Q4 Income From Operations | Beat | $19.62 mln | -$7.32 mln (4 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Curis Inc is $17.00, about 1,985.6% above its March 18 closing price of $0.82
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
